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Abstract There are several traditional and well-developed
methods for analyzing the activity of transcription factors,
such as EMSA, enzyme-linked immunosorbent assay, and
reporter gene activity assays. All of these methods have
their own distinct disadvantages, but none can analyze the
changes in transcription factors in the few cells that are
cultured in the wells of 96-well titer plates. Thus, a new
microsphere-based immunoassay to measure the activity of
transcription factors (MIA-TF) was developed. In MIA-TF,
NeutrAvidin-labeled microspheres were used as the solid
phase to capture biotin-labeled double-strand DNA frag-
ments which contain certain transcription factor binding
elements. The activity of transcription factors was detected
by immunoassay using a transcription factor-specific
antibody to monitor the binding with the DNA probe.
Next, analysis was performed by flow cytometry. The
targets hypoxia-inducible factor-1α (HIF-1α) and nuclear
factor-kappa B (NF-κB) were applied and detected in this
MIA-TF method; the results that we obtained demonstrated
that this method could be used to monitor the changes of
NF-κB or HIF within 50 or 100 ng of nuclear extract.
Furthermore, MIA-TF could detect the changes in NF-κB
or HIF in cells that were cultured in wells of a 96-well plate
without purification of the nuclear protein, an important
consideration for applying this method to high-throughput
assays in the future. The development of MIA-TF would
support further progress in clinical analysis and drug
screening systems. Overall, MIA-TF is a method with high
potential to detect the activity of transcription factors.
Keywords transcription factor.microsphere-based
immunoassay.NF-κB.HIF-1
1 Introduction
Transcription factors (TFs) are nuclear proteins that bind to
the elements upstream of promoter genes, thereby regulat-
ing gene expression [1]. Thus, aberrant activity of TFs
(such as oncogenic transcription factors) may lead to a
broad range of dysfunctions of human and animal cells,
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DOI 10.1007/s12575-010-9030-zcausing diseases such as cancers [2, 3]. Therefore, TFs are
potential cellular bioindicators for medical diagnosis and
targets for drug development [4]. Examples of such
important TFs are nuclear factor-kappa B (NF-κB) and
hypoxia-inducible factor-1 (HIF-1).
To analyze the potential activation of transcription factors
in tumors, it is necessary to develop a simple method to
measure the DNA binding capacity of target proteins.
Although Western blotting is a good method to detect the
content of specific proteins, it can only provide information
regarding the total number of the target TFs. Western blotting
cannot be used to distinguish between active or inactive TFs
[5]. The activity of transcription factors are not always
correlated with the TF amounts present in the cells; only the
active TFs bound to the transcription factor binding site
represent instances of gene expression [6]. Electrophoresis
mobility shift assay (EMSA) is the current method used to
detect the activity of TFs. Essentially, dsDNA probes
containing the TF binding sequences are labeled with the
[
32P]-radioisotope, and the activity of TFs is determined after
electrophoresis based on radioactivity levels. In addition,
non-radioactive EMSA has been developed, but it is limited
by high background and long detection time [5]. Although
EMSA can be used to measure the activity of TFs, the
devices required and steps of the EMSA procedure do not
provide possibilities to develop a high-throughput assay.
Although modified enzyme-linked immunosorbent assay
(ELISA) assays were developed for measuring the activity
of transcription factors in nuclear proteins [7], the procedures
for extracting nuclear proteins hindered the application of a
high-throughput platform. A reporter gene assay, using
transfection of plasmids that contain a mini-promoter with
several copies of TF binding elements followed by reporter
genes (such as luciferase and GFP), can also be used to
determine the activity of TFs in cultured cells. The trans-
fectants generated by reporter plasmids can be used to detect
the changes in the activity of TFs after treatment with drugs.
Therefore, this technique is suitable for use in high-
throughput assays for new drug discovery. However, the
efficiency of transfection of variant cells is unreliable and
ranges from susceptible to resistant. This variable efficiency
may lead to false results when the activity of TFs is
compared between different cells.
NF-κB is a transcription factor that controls the expression
of genes involved in cell proliferation, cycle progression,
invasion, angiogenesis, metastasis, apoptosis suppression,
multiple drug resistance, and inflammatory response in tumor
cells [8]. HIF-1 is another TF that regulates gene expression
in response to hypoxia and is involved in angiogenesis/
vascular remodeling, erythropoiesis, glucose transport, gly-
colysis, iron transport, and cell proliferation/survival [9, 10].
These two TFs were our targets to validate the method we
developed to measure the activity of TFs in cells. In this
study, NeutrAvidin-labeled microspheres were used as the
solid phase to capture the biotin-labeled double-stranded
DNA with TF responded elements on it. The flowchart in
Fig. 1a depicts the strategy to probe the binding activity of
transcription factors using this modified microsphere-based
immunoassay. The biotin-labeled dsDNA probes were first
made to react with a nuclear extract of the cells. Later,
subsequent to blocking with polyethylene glycol (PEG),
NeutroAvidin microspheres were added to the reactions.
After incubation, the mixtures were probed with an anti-
transcription factor antibody, washed by centrifugation,
detected with a fluorescent secondary antibody, and washed
again. Finally, the microspheres were analyzed using flow
cytometry. In addition to analyzing the nuclear extract, MIA-
TF can be also used to analyze the activity of TFs from total
cell lysates of cells cultured in a 96-well culture plate. This
may lead to the application of MIA-TF as a high-throughput
assay to enable further progress in clinical analysis and drug
screening systems.
2 Material and Methods
2.1 Antibodies and Reagents
Rabbit anti-human NF-κB p50 antibody was purchased
from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA,
USA). Fluorescein isothiocyanate (FITC)-conjugated goat
anti-rabbit antibody was purchased from Jackson Immu-
noResearch Laboratories, Inc. PA, USA. Goat anti-mouse
FITC-labeled antibody was purchased from Chemicon
International, Inc. (Temecula, CA, USA). Mouse anti-
human HIF-1α monoclonal antibody was purchased from
R&D systems, Inc. (Minneapolis, Minnesota, USA).
Deferoxamine mesylate salt (DFO) and hydroquinone
were purchased from Sigma Corporation (St Louis, MO,
USA). FluoSpheres NeutrAvidin™-labeled microspheres
were purchased from Invitrogen (Carlsbad, California, USA).
2.2 DNA Probe Preparation
Five types of double-stranded oligonucleotides were used
in this study. These were biotin-labeled double-stranded
DNA (dsDNA) containing seven times HIF binding site
(HBS), biotin-labeled dsDNA containing five times NF-κB
binding site (NBS), non-biotin-labeled HBS (cHBS), non-
biotin-labeled NBS (cNBS), and non-biotin-labeled dsDNA
VP16 without HBS and NBS (VP16). The HBS probe and
cHBS probe were prepared by PCR using the pCRII-C2-9
vector which was constructed by our lab and the following
primer pairs: 5′-Biotin-GCATCAAGCTTGGTACCG-3′ as
the forward primer and 5′-AGCTATCGATATCTGCA
GAATTCGG-3′ as the reverse primer for the HBS probe;
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and 5′-AGCTATCGATATCTGCAGAATTCGG-3′ as the
reverse primer for the cHBS probe. The NBS and cNBS
probes were prepared by PCR using the pNF-κB-hrGFP
vector (Stratagene Corporation, Cedar Creek, TX, USA) and
the following primer pairs: 5′-Biotin-TCATGTCTGGATC
CAAGCTA-3′ as the forward primer and 5′-CCGGGGATC
CATCTA GATTACCCTCTAGAGTCT-3′ as the reverse
primer for the NBS probe; 5′-TCATGTCTGGATCCA
AGCTA-3′ as the forward primer and 5′-CCGGGGATC
CATCTA GATTACCCTCTAGAGTCT-3′ as the reverse
primer for the cNBS probe. The VP16 probe was prepared
by PCR using the pCMV-ampR-linker-VP16 vector which
was constructed by our lab and the primer pair below: 5′-
TATCCTGCAGTCCGCGTACAGCCGCGCG-3′ as the
forward primer and 5′-TGACCTCGAGCTACCCACCG
TACTCGTCAA-3′ as the reverse primer for VP16 probe.
The sequences of DNA probes are given below:
HBS probe:
Biotin-gcatcaagcttggtaccgagctcggatccactagtaacggccgc
cagtgtgctggaattcggcttgtt ggagtgtacgtgtgtgctcccccagg
cattggttgttggagtgtacgtgtgtgctcccccaggcatggttgttgg agtg
tacgtgtgtgctccccaggcatggttgttggagtgtacgtgtgtgctccc cagg
catggttgttggagtg tacgtgtgtgctcccccaggcatggttgttggagtg
tacgtgtgtgctccccaggcatggttgttggagtgtacgtgt gtgctcccccagacg
tatatacgtatataagccgaattctgcagatatcgatagct (the bold sequences
indicate the HIF binding sites).
NBS probe:
Biotin-tcatgtctggatccaagctaggggactttccgcttggg
gactttccgctggggactttccgctggggactttccg ctggggactttccgcgga
gactctagagggtatataatggatccccgg (the bold sequences indicate
the NF-κB binding sites).
VP16 probe:
Tatcctgcagtccgcgtacagccgcgcgcgtacgaaaaacaattacgggtct
accatcgagggcctgctcgatctcccggacgacgacgcccccgaag
aggcggggctggcggctccgcgcctgtcctctccccgcgggacacacgcgca
gactgtcgacggcccccccgaccgatgtcagcctgggggacgagctccactta
gacggcgaggacgtggcgatggcgcatgccgacgcgctagacgatttcgacg
gacatgttgggggacggggattccccgggtccgggatttaccccccacgact
ccgccccctacggcgctctggatatggccgacttcgagtttgagcagatgtttaccg
atgcccttggaattgcggtacggtgggtagctcgaggtca.
Fig. 1 Experimental design of a
microsphere-based immunoas-
say for measuring the activity of
transcription factors (MIA-TF). a
Flowchart of MIA-TF. The
biotin-labeled dsDNA probes
were made to react with TFs in a
nuclear extract of the cells.
Subsequently, NeutrAvidin
microspheres were added into
the reactions. After incubation,
the mixtures were probed with
anti-transcription factor anti-
body and detected with a
fluorescent secondary antibody
by flow cytometry. b Dot plot
(SSC vs. FSC) of the MIA-TF
method. The DNA-bound TFs
were detected by an immunoas-
say using a transcription factor-
specific antibody and then
analyzed using flow cytometry.
Microspheres not incubated with
nuclear extract were used as
negative controls (left) to gate
the range of effective signals
(R1). The microspheres incubat-
ed with the nuclear extracts
increased the fluorescence
values in the range of effective
signals (right). bio-DNA
biotin-labeled dsDNA,
TF transcription factor
20 Lin et al.The cHBS and cNBS probes were used for a specific
competition test, and VP16 was used for a nonspecific
competition test.
2.3 Cell Culture
The human cervical cancer HeLa cell line was purchased
from the American Type Culture Collection (Manassas,
VA, USA). The HeLa cells were cultured in Dulbecco’s
modified Eagle medium (DMEM) supplemented with
10% fetal bovine serum, 100 U/ml of penicillin/strepto-
mycin, and 10% (w/v) of sodium hydrocarbonate. The
cells were incubated at 37°C in a humidified atmosphere
of 5% CO2.
2.4 Drug Treatment
The iron-chelator desferrioxamine (DFO) induces HIF-1α
in normoxia. DFO prevents HIF-1α from proteolysis by
inhibiting the activity of iron-dependent prolyl hydroxy-
lases [11]. To activate HIF-1, HeLa cells were seeded (1×
10
5 cells per well) in a 24-well plate and cultured in
DMEM for 8 h. Cells were treated with 100 μM of DFO in
triplicate and then incubated for 16 h at 37°C. Hydroqui-
none, a reactive metabolite of benzene, is known to inhibit
NF-κB activity. The cells were also treated with 25 μMo f
hydroquinone in triplicate and then incubated for 16 h at
37°C. After the medium was aspirated from the wells, the
cells were rinsed with phosphate-buffered saline (PBS) and
lysed with lysis buffer (10 mM 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES), 1.5 mM magne-
sium chloride (MgCl2), 10 mM potassium chloride (KCl),
1 mM DTT, 10% (v/v) protease inhibitor cocktail, and 0.1%
(v/v) Nonidet P-40).
2.5 Nuclear Extract
After incubation with or without the target drugs, the HeLa
cells were scraped into DMEM medium, washed in cold
PBS, and centrifuged at 500×g for 5 min. Next, HeLa cells
at a concentration of 2.5×10
7 cells/ml were lysed in lysis
buffer (10 mM HEPES), 1.5 mM MgCl2, 10 mM KCl,
1 mM DTT, 10% (v/v) protease inhibitor cocktail, and 0.1%
(v/v) Nonidet P-40) by pipetting up and down. The lysed
cells were centrifuged in a microcentrifuge tube at
16,000×g for 5 min at 4°C, and the cytosolic supernatant
was removed. The nuclear pellet, consisting of 1×10
8 cells/
ml, was dissolved in extraction buffer (20 mM HEPES,
1.5 mM MgCl2, 0.42 M NaCl, 0.2 mM EDTA, 25% (v/v)
glycerol, 1 mM DTT, and 1% (v/v) protease inhibitor
cocktail), incubated for 30 min on ice, and centrifuged at
16,000×g for 5 min [12]. The supernatants containing
nuclear proteins were collected and stored at −80°C. The
protein concentrations were determined by the Coomassie
Plus (Bradford method) protein assay reagent (Pierce, Oud-
Beijerland, the Netherlands) according to the manufacturer’s
instructions.
2.6 Development of the MIA-TF System
Exactly 1.5×10
−11 nmol of FluoSpheres NeutrAvidin™-
labeled microspheres were mixed with PEG to a final
concentration of 25 mM to block the microspheres in each
reaction. After incubation at room temperature for 30 min,
the blocked microspheres were diluted to 100 μl with
bovine serum albumin (BSA) buffer (1% BSA in PBS) and
centrifuged at 9,300×g for 5 min. The supernatant was
decanted and discarded; the pellet was then resuspended
with 10 μl PBS.
Biotin-labeled dsDNA (1.5×10
−8 nmol), prepared as
described in the DNA probe preparation section, was added
to an appropriate concentration of nuclear extract. The final
volume of the reaction was adjusted with extraction buffer to
30 μl and incubated at room temperature for 30 min. The
same amount of non-biotin-labeled dsDNA was added at the
same step. After 30 min of incubation, the prepared micro-
spheres were added to each sample and shaken gently for
15 min at room temperature. The sample was washed with
500 μl of washing buffer (0.02% Tween-20 in PBS) and then
centrifuged at 9,300×g for 5 min. After carefully discarding
the supernatant, 40 μl of the primary antibody was added to
each tube and incubated at room temperature for 1 h. After
centrifugation at 9,300×g for 5 min, the supernatant was
discarded. Next, 500 μl of washing buffer was added into
the sample, and the sample was centrifuged once more to
remove the supernatant. Then, 40 μl of the secondary
antibody (2.5 μg/ml in 1% BSA buffer) was added to each
tube and incubated at room temperature for another 1 h.
After the washing steps, the sample was resuspended in
500 μl BSA buffer and was ready for flow cytometry
(Becton Dickinson, Mountain View, CA, USA). The
parameters for the measurement of fluorescence intensity
were as follows:
Param Detector Voltage Amp/Gain Mode
P1 FSC E01 7.00 Lin
P2 SSC 545 1.00 Lin
2.7 Whole Cell Extract
HeLa cells were seeded (3,500 cells per well) in a 96-well
plate. After incubation for 24 h, cells were scraped in
medium, washed in cold PBS, and centrifuged at 500×g for
5 min. The cells were extracted in 50 μl of whole cell
extraction buffer (20 mM HEPES, 20% (v/v) glycerol, 1%
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phenylmethylsulfonyl fluoride, 1 mM DTT, and 10% (v/v)
protease inhibitor cocktail) by pipetting up and down and
incubated on ice for 20 min. After centrifugation at
3,700 rpm (Swing-bucket rotor A-2-DWP, Eppendorf,
Hamburg, Germany) for 5 min, the whole cell extract
was in the supernatant, the sample was analyzed by
modified-MIA-TF after the protein concentrations of the
whole cell extracts were dete r m i n e db yt h eC o o m a s s i e
Plus (Bradford method) protein assay reagent (Pierce,
Oud-Beijerland, the Netherlands) as specified in the
instruction manual.
2.8 MIA-TF Directly Detect Transcription Factor
in 96-Well Plates
Each well of 96-well microtiter plates was blocked with
300 μl of PBS buffer containing 5% BSA (BSA buffer) at
room temperature for 1–2 h. Then, the BSA buffer in each
well was discarded and the plate was washed three times with
PBST buffer (0.05% Tween-20 in PBS buffer). MIA-TF
was performed in the prepared 96-well microtiter plate.
Briefly, the whole cell lysate was transferred into the wells
of the blocked 96-well microtiter plate, and the blocked
microspheres were added and mixed gently for 15 min.
After centrifugation at 3,500 rpm for 5 min, the superna-
tant was carefully discarded and 40 μl of the primary
antibody was added into each well and allowed to
incubate at room temperature for 1 h. The wash procedure
described above was repeated using centrifugation; 40 μl
of the secondary antibody (2.5 μg/ml in 1% BSA buffer)
was then added to each well and incubated at room
temperature for 1 h. The samples were washed, resuspended
in 200 μl BSA buffer, and finally their fluorescent activity
was determined by flow cytometry.
2.9 Statistical Analysis
Data were analyzed using the SAS statistical software
package (SAS Institute, Inc., Cary, NC, USA). The results
were expressed as the mean ± SD. Differences in mean
values were evaluated by a one-way ANOVA. The level of
significance considered was p<0.05.
3 Results
3.1 Strategy for the Microsphere-Based Immunoassay
for Measuring the Activities of Transcription Factors
The dot plot (forward scatter vs. side scatter) of micro-
spheres without incubation with the nuclear extract was the
negative control used to gate the range of effective signals
(R1) and to exclude interference in the buffer (Fig. 1b). The
results indicated that the nuclear extract caused the of SSC
and FSC values of the microspheres to increase (Fig. 1b).
The effects may be due to the binding activity of the DNA
binding proteins in nuclear extract.
3.2 Determining the Activity of Transcription Factors
in Nuclear Extracts by MIA-TF
To test whether the MIA-TF method can be used to
detect the activity of transcription factors in the nuclear
extracts of cells, the NF-κB probe (NBS: dsDNA fragment
with biotin-labeled and containing NF-κB binding ele-
ments) was first used to detect the NF-κB activity in the
nuclear extracts of cells. The results showed that the
fluorescence values of microspheres incubated with nuclear
extracts were higher than those of microspheres incubated
without nuclear extracts for NBS. The increase in fluores-
cence could be abolished by non-biotin-labeled NBS
(cNBS), but was not decreased using unrelated competitive
dsDNA fragments with the VP16 binding element (Fig. 2a).
Another probe, the HIF binding element, HBS, was also
used to validate the effects of MIA-TF for the activity of HIF
in nuclear extracts. The results also indicated that the HBS
probe could be used to detect the activity of HIF as a NBS
probe (Fig. 2b).
3.3 The Sensitivity of MIA-TF
Recombinant human NF-κB proteins (rhNF-κB) were used
to determine the sensitivity of the MIA-TF method. The
results showed that more than 0.5 ng of rhNF-κB
significantly increased the relative fluorescence in a
dosage-dependent manner (Fig. 3a). Moreover, the sensi-
tivity of the MIA-TF method for NF-κB in the nuclear
extracts was also determined, and the results indicate that
the MIA-TF method measured the activity of NF-κBi n
50 ng of the nuclear extracts. The increases in fluorescence
activity were correlated to the amounts of nuclear extracts,
which ranged from 50 to 1,000 ng (Fig. 3b). In contrast, the
HBS probe showed effective sensitivity that ranged from
100 to 1,000 ng for the activity of HIF in the nuclear
extracts (Fig. 3c).
3.4 Determining the Effects of Drugs on the Activity
of Transcription Factors Using the MIA-TF Method
Hydroquinone is an inhibitor that suppresses the activity of
NF-κB. To monitor whether the MIA-TF method could
detect the effects of drugs on the activity of TFs, cells were
treated with hydroquinone (25 μM) and the nuclear extracts
were assayed. We observed that the suppression of NF-κB
activity by hydroquinone was detectable using the MIA-TF
22 Lin et al.assay system (Fig. 4a). DFO, an inducer of HIF, was also
used to verify the MIA-TF assay for evaluating the effects
of drugs on the activity of TFs. The ability of DFO to enhance
the activity of HIF was confirmed using the MIA-TF method
(Fig. 4b).
3.5 The Activity of Transcription Factors in Cells were
Displayed Using the MIA-TF Method in a 96-Well Culture
Plate
The results described above revealed that the MIA-TF
method could determine the activity of TFs in nuclear
extracts. For application in a high-throughput system, we
needed to determine whether the MIA-TF method could be
used to analyze the effects of drugs on cells that were
cultured in 96-well plates.
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be used to explore the NF-κB activity of cell lysates in a
96-well plate, even with only 3,500 cells per well (Fig. 5).
In addition, the reduced fluorescence of the group subjected
to hydroquinone treatments were also displayed using the
MIA-TF method (Fig. 5).
4 Discussion
A convenient, sensitive, and specific MIA-TF assay was
developed to detect the intracellular activity of TFs. MIA-
TF could detect the activity of TFs from 50 ng of nuclear
extracts (Fig. 2a, b). Because this method provided the
fluorescent values in a dosage model, it also determined the
precise amount of active TFs in the presence of a TFs
standard (Fig. 3). Thus, the MIA-TF method may be a good
system to determine the degree of tumorigenicity [13] and
cellular physiology [14]. Furthermore, this assay could be
used to measure the activity of TFs from the cell lysates
without extracting nuclear proteins (Fig. 5), an important
point when considering its application in the discovery of
new drugs using a high-throughput platform [15].
The MIA-TF method has several advantageous charac-
teristics, including fast detection, high sensitivity, specific
detection, and flexible as well as wide application. Several
blocking reagents were tested to circumvent the false
positive signals resulting from nonspecific binding of TFs
to microspheres; PEG provided the best blocking effect
[16]. The 3,500 cells cultured per well in a 96-well plate
were directly lysed with cell lysis buffer to obtain about
500 ng whole cellular proteins; the activity of TFs of the
latter was directly determined in the well (Fig. 5). Although
whole nuclear proteins can be detected using ELISA which
was created by Jagelska et al. [17], the advantage of the
MIA-TF method is that it works without the requirement to
purify the nuclear proteins. Furthermore, the MIA-TF
method could be conveniently extended to measure any
interesting TFs by simply switching the dsDNA probe; it is
possible to synthesize short DNA primer pairs with the
binding elements of TFs and using specific antibodies.
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and the activity of transcription factors in cell lysates in 96-well plates
was measured. The results are expressed as mean ± SD. *p<0.05,
n=6.NBS biotin-labeled dsDNA containing five times NF-κB-binding
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Fig. 4 MIA-TF detected the activity of transcription factors in cells
after drug treatment. a After treatment with 25 μM hydroquinone for
16 h, the MIA-TF method was used to detect the changes of NF-κB
expression in HeLa cells. b After treatment with 100 μM desferriox-
amine (DFO) for 16 h, the MIA-TF method was also used to detect
the changes of HIF-1 expression in HeLa cells. The results are
expressed as mean ± SD. *p<0.05, n=6. NBS biotin-labeled dsDNA
containing five times NF-κB-binding sites, HBS biotin-labeled
dsDNA containing seven HIF-binding sites
24 Lin et al.ELISA-based kits were used for the detection and
quantification of TF activation. Both nuclear and whole
cell extracts could be assayed using such kits. ELISA has
limitations, like the need for a large sample volume, a
narrow dynamic range, and complicated dilution proce-
dures [18, 19]. No matter which kit is used, the optimal
detection of TF activity ranges between 0.5 and 100 µg of
nuclear extract. Wang et al. [20] showed that the detection
range was between 0.625 and 10 µg of nuclear extract. In
our study, the sensitivity of TF activity was quantified as
about 0.05–2 µg of nuclear extract. de Jager and Rijkers
[21] also indicated that the cytokine detection of bead-
based multiplex immunoassays (MIA) was more sensitive
than ELISA. Therefore, a three-dimensional solid carrier
may be better than the plane-solid carrier to decrease the
conformational barriers and raise the sensitivity.
Marligen Biosciences (www. marligen.com) has developed
a multiplex TF assay that uses TF probes to determine
changes in signaling pathways. The design of the multiplex
TF assay is similar to our MIA-TF assay. Theoretically, the
multiplex TF assay can be used to detect the activation of
different TFs in a single sample by distinguishing between the
reactions with different fluorescent microspheres or
fluorescence-labeling probes, a useful design for multiple
detections of TFs. Like the multiplex TFs assay, the MIA-TF
method also can be used to determine the activation of
different TFs using a single sample as long as it is
combined with antibodies labeled with different fluores-
cent quantum dots. However, the MIA-TF method has
more advantages than the multiplex TF assay. First, the
sensitivity of the MIA-TF method was higher: the
multiplex TFs assay needs at least 500 ng of nuclear
extracts for the detection of TF activity according to the
instructions, while the MIA-TF method detected the
activity of TFs using 50 ng of nuclear extracts (Fig. 3).
Although the multiplex TF assay can be used to perform
the reactions in a microtiter plate when combined with the
nuclear extraction kit, the MIA-TF assay directly mea-
sured the activity of TFs from the whole cell lysates in the
96-well microtiter plates. In addition, the multiplex TF
assay method highlighted the differences between the TF-
bound probe and the unbound probe by the addition of a
“proprietary reagent” provided by the company. Without
antibody recognition, this proprietary reagent could interfere
with the TFs by nonspecific binding of certain DNA binding
proteins. In comparison, analysis using the MIA-TF method
provided sensitive and reliable detection of the activity of TFs.
5 Conclusion
Previously, researchers developing microsphere-based
assays used captured antibodies bound to an immobile
phase on polystyrene microspheres for multiplexed assays
of cytokines, antibodies, hormones, nucleic acids, viruses,
and other biomolecules [22, 23]. The new MIA-TF method
we developed for TF detection shows potential in furthering
progress in clinical analysis and drug screening. Overall,
the MIA-TF method is a highly promising method for
detecting the activity of TFs.
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